Baseline type 2 biomarker levels and response to tezepelumab in severe asthma

2021114 citationsJournal Articlehybrid Open Access

Authors

Jonathan Corren · University of California, Los Angeles

Tuyet‐Hang Pham · AstraZeneca (United States)

Esther García Gil · AstraZeneca (Spain)

Kinga Sałapa · AstraZeneca (Poland)

Pin Ren · AstraZeneca (United States)

Jane R. Parnes · Amgen (United States)

Gene Colice ·

Abstract

At baseline, positive correlations between specific T2 inflammatory biomarkers were observed. Tezepelumab reduced multiple T2 inflammatory biomarkers, which indicates decreased airway inflammation, and reduced exacerbations irrespective of baseline T2 biomarker profiles in patients with severe asthma.

Topics & Keywords

Asthma and respiratory diseases IL-33, ST2, and ILC Pathways Allergic Rhinitis and Sensitization

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Allergy

Volume 77, Issue 6, pp. 1786-1796

DOI: 10.1111/all.15197

Field-Weighted Citation Impact: 9.34